S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The Retirement of Your Dreams Awaits You… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The Retirement of Your Dreams Awaits You… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The Retirement of Your Dreams Awaits You… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The Retirement of Your Dreams Awaits You… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

$1.58
+0.11 (+7.48%)
(As of 02/23/2024 ET)
Today's Range
$1.46
$1.58
50-Day Range
$1.46
$2.12
52-Week Range
$1.03
$2.29
Volume
51,715 shs
Average Volume
80,935 shs
Market Capitalization
$142.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Biodesix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.5% Upside
$3.50 Price Target
Short Interest
Healthy
0.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$173,034 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.65) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

438th out of 942 stocks

Medical Laboratories Industry

12th out of 21 stocks


BDSX stock logo

About Biodesix Stock (NASDAQ:BDSX)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

BDSX Stock Price History

BDSX Stock News Headlines

Biodesix (BDSX) Set to Announce Earnings on Friday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biodesix Inc CEO Scott Hutton Sells 64,390 Shares
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here's what Wall Street expects from Biodesix's earnings
Jack Schuler Spends US$217k On Biodesix Stock
See More Headlines
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/24/2024
Next Earnings (Confirmed)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BDSX
Fax
N/A
Employees
245
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$3.50
Low Stock Price Target
$3.50
Potential Upside/Downside
+121.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-65,450,000.00
Net Margins
-143.88%
Pretax Margin
-143.88%

Debt

Sales & Book Value

Annual Sales
$44.03 million
Book Value
$0.27 per share

Miscellaneous

Free Float
32,752,000
Market Cap
$142.95 million
Optionable
Optionable
Beta
1.24
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














BDSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings
or view top-rated stocks.

What is Biodesix's stock price target for 2024?

3 analysts have issued 12-month price objectives for Biodesix's stock. Their BDSX share price targets range from $3.50 to $3.50. On average, they anticipate the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 121.5% from the stock's current price.
View analysts price targets for BDSX
or view top-rated stocks among Wall Street analysts.

How have BDSX shares performed in 2024?

Biodesix's stock was trading at $1.84 at the start of the year. Since then, BDSX stock has decreased by 14.1% and is now trading at $1.58.
View the best growth stocks for 2024 here
.

Are investors shorting Biodesix?

Biodesix saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 196,700 shares, an increase of 32.9% from the January 15th total of 148,000 shares. Based on an average daily volume of 111,400 shares, the short-interest ratio is currently 1.8 days. Currently, 0.8% of the shares of the company are short sold.
View Biodesix's Short Interest
.

When is Biodesix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our BDSX earnings forecast
.

How can I listen to Biodesix's earnings call?

Biodesix will be holding an earnings conference call on Friday, March 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. The business had revenue of $9.61 million for the quarter, compared to analyst estimates of $10.70 million. Biodesix had a negative trailing twelve-month return on equity of 1,387.19% and a negative net margin of 143.88%. During the same period in the prior year, the firm posted ($0.49) EPS.

When did Biodesix IPO?

(BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Biodesix's major shareholders?

Biodesix's stock is owned by a variety of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (5.15%), Worth Venture Partners LLC (1.26%), Essex Investment Management Co. LLC (1.01%), Vanguard Group Inc. (0.90%), Opaleye Management Inc. (0.55%) and Bridgeway Capital Management LLC (0.25%). Insiders that own company stock include Charles M Watts, Chris Vazquez, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton.
View institutional ownership trends
.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDSX) was last updated on 2/24/2024 by MarketBeat.com Staff